Phase I-II
A phase 1/2, open-label, safety and dosing study of autologous CART cells (desmoglein 3 chimeric autoantibody receptor T cells [DSG3-CAART] or CD19-specific Chimeric Antigen Receptor T cells [CABA-201]) in subjects with active, pemphigus vulgaris
- Study HIC#:2000038237
- Last Updated:03/24/2026
- Age18 years and older
- GenderBoth
Contact Us
For more information about this study, including how to volunteer, contact:
Andrea DeClement
Help Us Discover!
You can help our team find trials you might be eligible for by creating a volunteer profile in MyChart. To get started, create a volunteer profile, or contact helpusdiscover@yale.edu, or call +18779788343 for more information.
